As reported on Science Daily, researchers at the University of Michigan have identified a potential new therapeutic approach for aggressive prostate cancers that become resistant to standard hormone-targeting treatments. Preclinical…
GPRC5D-Targeting Approach Positions Company to Expand Post-BCMA Treatment Options As reported on Fierce BioTech, Bristol Myers Squibb announced positive results from its pivotal Quintessential trial evaluating arlocabtagene autoleucel, a genetically…
Editor's Note: We're honored to share the following article from our friends at the Courageous Parents Network. To see this article in its original format, please click here. Parents will…
Editor's Note: Patient Worthy is honored to share this article from Rareatives, originally written by our friend Jessica Lynn. To see the article in its original format, please click here.…
Editor's Note: Patient Worthy is honored to share this story from our friends at Elephants & Tea, originally written by Bill Phillips, a colorectal cancer survivor. To see the article…
A single genetic change can have dramatically different effects from one person to the next. That is the reality for people living with PTEN hamartoma tumour syndrome (PHTS), a rare…
As reported on QZ, the U.S. Food and Drug Administration has approved a new indication for Eli Lilly’s tirzepatide (Mounjaro), allowing the therapy to be used to reduce the risk…
As reported on MedCity News, the U.S. Food and Drug Administration has approved Takeda Pharmaceutical’s Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare…
As reported on Drugs, BioNTech has decided to halt development of its Phase 2 BNT122-01 study investigating autogene cevumeran (BNT122/RO7198457) in patients with resected colorectal cancer who remained ctDNA-positive after…
As reported on PharmaBiz, BeOne Medicines has reported positive results from the second interim analysis of the phase 3 HERIZON-GEA-01 trial, further supporting the use of zanidatamab (Ziihera)-containing regimens as…
At 22, a young person's world should be filled with possibilities—a career to build, places to travel, friendships to make, and a future to imagine. Instead, this young man, David,…
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has granted approval to PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythaemia (ET), providing…
In a recent press release, Novartis has reported positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials, showing that the investigational oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib…
As reported on Business Wire, the European Commission has approved trastuzumab deruxtecan (Enhertu) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.…
As reported in the European Medical Journal, Novartis has paused eight clinical studies evaluating its experimental CAR-T cell therapy, known as rap-cell, after three trial participants died following severe immune-related…
As reported in the European Medical Journal, new research suggests that cherry angiomas occur more frequently and at an earlier age in people with neurofibromatosis type 1 (NF1), raising the…
In a recent press release, BioCryst Pharmaceuticals has shared that it received approval from Japan’s Ministry of Health, Labour and Welfare for the use of ORLADEYO® (berotralstat) as a preventive…
As reported on Inside Precision Medicine, a new, non-invasive test may help doctors detect oral cancer quickly and reduce the need for painful scalpel biopsies. In a large study involving…
Have you ever looked in the mirror and wondered, “Who am I now? Why did this diagnosis happen to me? When will this be over? Who will ever love me…
As reported on Pharma Phorum, Roivant Sciences and its subsidiary Priovant Therapeutics have received U.S. Food and Drug Administration (FDA) approval for Lisraya (brepocitinib), marking the first targeted treatment specifically…
As reported on Business Wire, AstraZeneca has finalized its previously announced licensing agreement with Dizal Pharmaceutical, gaining exclusive worldwide rights to develop and market ZEGFROVY (sunvozertinib), an oral, irreversible epidermal…
Treating acute ischemic strokes involves a precarious clinical balance: physicians must dissolve arterial clots to save brain tissue without triggering catastrophic intracranial hemorrhaging. To address the severe bleeding risks associated…
Editor's Note: Patient Worthy is honored to share the following article, originally published by our friends at CURE SYNGAP1. To see the article in its original format, please click here.…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
